Specialty pharmaceutical firm Elorac, which is involved in the development and commercialization of products for dermatology, allergy and oncology, has acquired Gideon Pharmaceuticals, a development-stage pharmaceutical company whose products use its patented Heprotect technology, which reduces the hepatotoxicity of hepatocellular toxic agents without interfering with their bioactivity. Among the drugs being developed by Gideon are Heprotect versions of acetaminophen, methotrexate, acitretin and...